ExCellThera announces additional data to be presented at Cord Blood Association 2020 international congress

MONTREAL, August 18, 2020 – ExCellThera Inc., a clinical stage cell and molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that additional data from a Phase I/II clinical trial using its lead technology, ECT-001 Cell Therapy, will be presented at Cord Blood Connect 2020, the annual international congress of the Cord Blood Association. The study, describing rapid and robust immune recovery in patients transplanted with the ECT-001 graft, was selected as Best Abstract for a virtual oral presentation.

Details of the presentation are as follows:

Date & Time: Thursday, September 17, 2020, 12:45 p.m. ET

Title: Single UM171-expanded cord blood transplants support robust T-cell reconstitution with low rates of severe infections

Lead Author: Maude Dumont-Lagacé, PhD, Scientific Coordinator – Immunology, ExCellThera

 

About ECT-001 Cell Therapy

The ECT-001 Cell Therapy technology is a combination of a small molecule, UM171, and an optimized culture system. The technology, capable of expanding the number of stem and immune cells exponentially in as little as seven days, is used in novel curative cord blood transplant therapies for patients with blood cancers, allowing rapid engraftment, greatly reduced incidence of transplant-related mortality, low risk of chronic graft-versus-host disease and low risk of relapse, resulting in better outcomes for patients.

About ExCellThera Inc.

ExCellThera is a clinical stage cell and molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for use in novel one-time curative therapies for patients with hematologic malignancies, autoimmune and other diseases. ExCellThera’s most advanced technology, ECT-001 Cell Therapy, combines a proprietary small molecule, UM171, and an optimized culture system. In pursuit of better treatments for patients, the company is building out its portfolio of products, as well as supporting best-in-class clinical trials. excellthera.com

Scroll to view